StockData
Merck & Co., Inc. logo

Merck & Co., Inc.

MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30242% above fair value
$148.36−1.16 (-0.78%)

Close on Nov 2, 2026Market cap $366.03BP/E 118.7Yield 2.21%

Merck Noxafil (posaconazole, legacy) — Worldwide sales by Quarter

Noxafil (posaconazole, legacy) — Worldwide sales ($M) ($M)

QuarterlyAnnual

Merck Noxafil (posaconazole, legacy) — Worldwide sales: $36M in Q4 2024, down 21.7% from a year earlier. That is the lowest of the 36 quarters on record here. No newer figure appears in the documents we track.

Latest, Q4 2024
36
Period ended Dec 31, 2024
Change on a year earlier
-21.7%
46 in Q4 2023
History
36 quarters
Since Q1 2016
Sources
8
Documents cited below

Where the Q4 2024 figure comes from

“|| Noxafil | 36 | 46 | -23 | -2 | 4 | -149 | 37 | 43 | -12”

Source: Form 8-K (tm255059d1_ex99-1.htm, filed 2025-02-04) ↗

Reported in Form 10-Q / 10-K Segment & Product Sales Footnote & Form 8-K Table 3 / 3a / 3b.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedNoxafil (posaconazole, legacy) — Worldwide sales ($M) ($M)Year on yearSource
Q4 2024Dec 31, 202436-21.7%Form 8-K (tm255059d1_ex99-1.htm, filed 2025-02-04) ↗
Q3 2024Sep 30, 202441-19.6%Form 8-K (tm255059d1_ex99-1.htm, filed 2025-02-04) ↗
Q2 2024Jun 30, 202445-18.2%Form 8-K (tm255059d1_ex99-1.htm, filed 2025-02-04) ↗
Q1 2024Mar 31, 202456-6.7%Form 8-K (tm255059d1_ex99-1.htm, filed 2025-02-04) ↗
Q4 2023Dec 31, 202346-20.7%Form 8-K (tm255059d1_ex99-1.htm, filed 2025-02-04) ↗
Q3 2023Sep 30, 202351-17.7%Form 8-K (tm255059d1_ex99-1.htm, filed 2025-02-04) ↗
Q2 2023Jun 30, 202355-8.3%Form 8-K (tm255059d1_ex99-1.htm, filed 2025-02-04) ↗
Q1 2023Mar 31, 202360+5.3%Form 8-K (tm255059d1_ex99-1.htm, filed 2025-02-04) ↗
Q4 2022Dec 31, 202258-6.5%Form 8-K (tm244517d1_ex99-1.htm, filed 2024-02-01) ↗
Q3 2022Sep 30, 202262-3.1%Form 8-K (tm244517d1_ex99-1.htm, filed 2024-02-01) ↗
Q2 2022Jun 30, 202260-9.1%Form 8-K (tm244517d1_ex99-1.htm, filed 2024-02-01) ↗
Q1 2022Mar 31, 202257-14.9%Form 8-K (tm244517d1_ex99-1.htm, filed 2024-02-01) ↗
Q4 2021Dec 31, 202162-24.4%Form 8-K (tm2227726d1_ex99-1.htm, filed 2022-10-27) ↗
Q3 2021Sep 30, 202164-19.0%Form 8-K (tm2227726d1_ex99-1.htm, filed 2022-10-27) ↗
Q2 2021Jun 30, 202166-9.6%Form 8-K (tm2227726d1_ex99-1.htm, filed 2022-10-27) ↗
Q1 2021Mar 31, 202167-28.7%Form 8-K (tm2227726d1_ex99-1.htm, filed 2022-10-27) ↗

Breakdown

What makes up noxafil (posaconazole, legacy) — Worldwide sales

Cite this data

StockData. (2026). Merck Noxafil (posaconazole, legacy) — Worldwide sales ($M), quarterly Q1 2016–Q4 2024 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/rev-noxafil

See every metric in the Merck KPI table. Data updated Oct 26, 2026.